✦ LIBER ✦

Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies

✍ Scribed by Olmos, D.; Barker, D.; Sharma, R.; Brunetto, A. T.; Yap, T. A.; Taegtmeyer, A. B.; Barriuso, J.; Medani, H.; Degenhardt, Y. Y.; Allred, A. J.; Smith, D. A.; Murray, S. C.; Lampkin, T. A.; Dar, M. M.; Wilson, R.; de Bono, J. S.; Blagden, S. P.

Book ID: 124091968
Publisher: American Association for Cancer Research
Year: 2011
Tongue: English
Weight: 988 KB
Volume: 17
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-10-2946

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

431 POSTER A phase I first-in-human stud

431 POSTER A phase I first-in-human study of the polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors

✍ S. Blagden; D. Olmos; R. Sharma; J. Barriuso; H. Medani; M. Versola; S. Murray; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 80 KB

A phase I, dose-escalation study of the

A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours

✍ Patrick Schöffski; Ahmad Awada; Herlinde Dumez; Thierry Gil; Sylvie Bartholomeus 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 245 KB

36 ORAL A Phase I single dose escalation

36 ORAL A Phase I single dose escalation study of the novel Polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours

✍ P. Schöffski; A. Awada; H. Dumez; T. Gil; S. Bartholomeus; J. Selleslach; M. Tat 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Phase I Study of Rigosertib, an Inhibito

Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer

✍ Ma, W. W.; Messersmith, W. A.; Dy, G. K.; Weekes, C. D.; Whitworth, A.; Ren, C.; 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 440 KB

Phase I and pharmacokinetic study of cap

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

✍ Maarten J. Deenen, Heinz-Josef Klümpen, Dick J. Richel, Rolf W. Sparidans, Marie 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 299 KB

Phase 1 study of MLN8054, a selective in

Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors

✍ E. Claire Dees; Jeffrey R. Infante; Roger B. Cohen; Bert H. O’Neil; Suzanne Jone 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 328 KB